Evidence mapPaperPMID 42589250Full record

ArticleInternational journal of molecular sciences2026

PCOS Serum Promotes Endometrial Cancer Cell Proliferation with Partial Involvement of IGF-Associated AKT/mTOR Signaling: A Pilot Translational Study with Exploratory Molecular Insights.

Neha Sharma, Mahmood Hachim, Syeda Sadaf Rizvi, Baila Samreen, Sumayya Inuwa, Tasneem AbuHajjaj, Fatima Ba Khamis, Fatma Alqutami, Aaron Han, Ibrahim Elrahman and 6 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Neha SharmaCollege of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, Dubai 505055, United Arab Emirates.
Mahmood HachimCollege of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, Dubai 505055, United Arab Emirates.ORCID 0000-0002-7096-0731
Syeda Sadaf RizviCollege of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, Dubai 505055, United Arab Emirates.
Baila SamreenCollege of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, Dubai 505055, United Arab Emirates.
Sumayya InuwaCollege of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, Dubai 505055, United Arab Emirates.
Tasneem AbuHajjajLatifa Hospital, Dubai Health, Dubai 505055, United Arab Emirates.
Fatima Ba KhamisLatifa Hospital, Dubai Health, Dubai 505055, United Arab Emirates.
Fatma AlqutamiCollege of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, Dubai 505055, United Arab Emirates.
Aaron HanCollege of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, Dubai 505055, United Arab Emirates.
Ibrahim ElrahmanKings College Hospital London, Dubai Hills, Dubai 505055, United Arab Emirates.
Aparna GummaMediclinic Parkview Hospital, Dubai 505055, United Arab Emirates.
Uloma OkwuosaKings College Hospital London, Dubai Hills, Dubai 505055, United Arab Emirates.
Komal HazariLatifa Hospital, Dubai Health, Dubai 505055, United Arab Emirates.
Muna TahlakCollege of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, Dubai 505055, United Arab Emirates.
Fadi G MirzaCollege of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, Dubai 505055, United Arab Emirates.
William AtiomoCollege of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, Dubai 505055, United Arab Emirates.

Funding

Mohammed Bin Rashid University of Medicine and Health Sciences MBRU-CM-RG2022-14
6 · The paper itself

Abstract

Women with polycystic ovary syndrome (PCOS) have a substantially increased risk of endometrial cancer (EC), yet the biological mechanisms underpinning this association, to support future prevention and therapeutics, remain incompletely understood. Insulin-like growth factor (IGF)-associated signaling has been implicated, but existing evidence is conflicting. In this pilot translational study, serum IGF1 and IGFBP-3 were measured in women with PCOS (

Indexed as

Endometrial NeoplasmsInsulin-Like Growth Factor IPolycystic Ovary SyndromeProto-Oncogene Proteins c-aktSignal TransductionTOR Serine-Threonine KinasesAdultCell Line, TumorCell ProliferationCell SurvivalFemaleHumansInsulin-Like Growth Factor Binding Protein 3Pilot ProjectsIGF1 protein, humanIGFBP3 protein, humanInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IMTOR protein, humanProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasescancerendometrialIGF1insulin-like growth factor onepolycystic ovary syndrome

Identifiers

PMID42589250
PMCPMC13466320

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.